Letters to the Editor

Responses to Treatment of Acute Migraine Headache Article



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 2011 Oct 1;84(7):728-738.

Original Article: Treatment of Acute Migraine Headache

Issue Date: February 1, 2011

Available at: http://www.aafp.org/afp/2011/0201/p271.html

to the editor: I read with interest the article on treatment of acute migraine headache, but I was surprised to find no mention of the combination of magnesium oxide and aspirin for migraine treatment.

When patients ask whether they should try certain medications of which I am not knowledgeable, such as this one, I inquire how they heard about them and request that they direct me to the source of any material they might have seen. Increasingly, that source is the Internet, rather than more authoritative and objective materials.

Doubtless the authors of this important article could not cover every remedy used for migraine, but I think they missed an opportunity to bring AFP readers and their patients up to date about the effectiveness of magnesium oxide plus aspirin.

Author disclosure: No relevant financial affiliations to disclose.

to the editor: I was pleased to see the review of therapies for acute migraine. Two clarifications may be useful for readers who prescribe the treatments covered in the article.

First, isometheptene-containing drugs are no longer available in the United States; all have been discontinued by the manufacturers. These older products were never approved by the U.S. Food and Drug Administration (FDA) for treatment of acute migraine.1 This action is consistent with the Healthy People 2020 medical product safety objective to decrease the number of pain medications that are not approved by the FDA.2

Second, the article reports the results of a meta-analysis of oral triptans that found that the most effective doses for pain relief were 10 mg of rizatriptan (Maxalt), 80 mg of eletriptan (Relpax), and 12.5 mg of almotriptan (Axert).3 This is not a clinically relevant comparison, however, because the highest approved single dose of eletriptan is 40 mg, not 80 mg. Although the 40-mg dose of eletriptan can be repeated later for a total of 80 mg per 24 hours, the meta-analysis compared a single dose of 80 mg with the listed approved doses of the other compounds. The meta-analysis did not demonstrate any meaningful advantages for eletriptan at the approved dose of 40 mg in comparison with those drugs.4

Author disclosure: No relevant financial afiiliations to disclose.

REFERENCES

1. American Society of Health-System Pharmacists Bulletin. http://www.ashp.org/drugshortages/NotAvailable/bulletin.aspx?id=275. Accessed August 5, 2011.

2. U.S. Department of Health and Human Services; HealthyPeople.gov. 2020 topics & objectives. Medical product safety. http://www.healthypeople.gov/2020/topicsobjectives2020/objectiveslist.aspx?topicid=27. Accessed February 15, 2011.

3. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001;358(9294):1668–1675.

4. Loder E. Triptan therapy in migraine. N Engl J Med. 2010;363(1):63–70.

to the editor: The article on treatment of acute migraine headache mentioned the use of intravenous dexamethasone as adjunctive therapy to prevent headache recurrence within 24 to 72 hours. I am concerned about two issues regarding the use of dexamethasone.

First, the dosage listed in Table 3 for intravenous dexamethasone is not consistent with the published meta-analyses.1,2 The randomized trials used 10 to 25 mg of dexamethasone intravenously, yet Table 3 lists the dosage as 4 to 10 mg intravenously.

Second, the authors indicate that one trial found oral dexamethasone to be similar in effectiveness to the parenteral form. However, the cited trial of a single oral dexamethasone did not find a reduced rate of recurrent headaches compared with placebo, except for a weak effect in the subgroup who presented less than 24 hours after the onset of symptoms.3 In addition, a trial of oral prednisone did not find any benefit.4

The use of dexamethasone to prevent a recurrent headache is appropriate for some patients, but the dosage needs to be sufficient and should be administered parenterally to likely provide any benefit.

Author disclosure: No relevant financial affiliations to disclose.

REFERENCES

1. Colman I, Friedman BW, Brown MD, et al. Parenteral dexamethasone for acute severe migraine headache: meta-analysis of randomised controlled trials for preventing recurrence. BMJ. 2008;336(7657):1359–1361.

2. Singh A, Alter HJ, Zaia B. Does the addition of dexamethasone to standard therapy for acute migraine headache decrease the incidence of recurrent headache for patients treated in the emergency department? A meta-analysis and systematic review of the literature [published correction appears in Acad Emerg Med. 2009;16(5):435]. Acad Emerg Med. 2008;15(12):1223–1233.

3. Kelly AM, Kerr D, Clooney M. Impact of oral dexamethasone versus placebo after ED treatment of migraine with phenothiazines on the rate of recurrent headache: a randomised controlled trial. Emerg Med J. 2008;25(1):26–29.

4. Fiessler F, Shih R, Silverman M, et al. Prednisone for migraine headaches: an emergency department randomized double-blind placebo-controlled trial. Acad Emerg Med. 2007;14(suppl 1):S71.

in reply: I would like to thank Drs. Blum, Loder, and Muncie for their comments and questions. Dr. Blum raises the question of the effectiveness of a combination of aspirin plus magnesium for abortive treatment of migraine. Two double-blind, placebo-controlled trials have shown that oral magnesium supplementation is effective in migraine prevention.1,2 Intravenous magnesium was effective as an abortive agent in patients with low ionized magnesium levels, but not in patients with normal magnesium levels.3

Aspirin, without magnesium, is used commonly as an abortive agent. A Cochrane review concluded that 1,000 mg of aspirin is an effective treatment for acute migraine headache.4 To my knowledge, no studies have evaluated the combination of aspirin plus magnesium. Therefore, I am unable to conclude if the combination is more or less effective than aspirin alone for abortive therapy.

I would like to thank Dr. Loder for noting that isometheptene-containing drugs (Midrin, Epidrin) have been discontinued and are no longer available in the United States. The U.S. Headache Consortium assigns isometheptene-containing compounds to group 2 in terms of evidence base for efficacy (i.e., moderate statistical and clinical benefit) on the basis of one double-blind, placebo-controlled study plus clinical impression of effect.5 It is still possible for patients to obtain isometheptene-containing medications if they are ordered through a compounding pharmacy that can make a drug with the same individual components as Midrin (325 mg of acetaminophen/100 mg of dichloralphenazone/65 mg of isometheptene).6

Dr. Loder also makes excellent comments regarding a meta-analysis of the efficacy of various triptans for treatment of acute migraine, noting that although 80 mg of eletriptan (Replax) is cited as an optimal dose, 40 mg is the maximal single dose approved by the U.S. Food and Drug Administration. The main point I wished to convey in that section of the article is that it is difficult to make evidence-based conclusions as to which triptan should be used first-line. A Cochrane review concluded that all triptans are similar in effectiveness and tolerability.7 Nonresponders to one triptan sometimes benefit from another, and, in practice, other factors (i.e., cost, route of administration, and pharmacokinetics) often determine the choice of triptan.

I would also like to thank Dr. Muncie for looking more closely into the issue of dexamethasone as adjunctive therapy for acute migraine. He correctly points out that a study of oral dexamethasone cited in a meta-analysis did not show impressive results. I agree that the evidence supports the use of parenteral—not oral—dexamethasone as an adjunctive treatment for acute migraine headache. Dr. Muncie is also correct that the doses used in the trials range from 8 to 24 mg, rather than 4 to 10 mg as listed in Table 3 of my article.

Author disclosure: No relevant financial affiliations to disclose.

REFERENCES

1. Peikert A, Wilimzig C, Köhne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia. 1996;16(4):257–263.

2. Facchinetti F, Sances G, Borella P, Genazzani AR, Nappi G. Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium. Headache. 1991;31(5):298–301.

3. Mauskop A, Altura BT, Cracco RQ, Altura BM. Intravenous magnesium sulfate relieves migraine attacks in patients with low serum ionized magnesium levels: a pilot study. Clin Sci (Lond). 1995;89(6):633–636.

4. Kirthi V, Derry S, Moore RA, McQuay HJ. Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2010;(4):CD008041.

5. Morey SS. Guidelines on migraine: Part 3. Recommendations for individual drugs. Am Fam Physician. 2000;62(9):2415–21482151.

6. Personal communication, Apothecary Pharmacy, Los Angeles, Calif. (310) 737-7277. July 22, 2011; Town Total Health Pharmacy, New York, NY. (212) 213-5570. July 22, 2011; Good Life Health Services, Ord, Neb. (308) 728-3295, July 22, 2011.

7. McCrory DC, Gray RN. Oral sumatriptan for acute migraine. Cochrane Database Syst Rev. 2003;(3):CD002915.

Send letters to Kenneth W. Lin, MD, MPH, Associate Deputy Editor for AFP Online, e-mail: afplet@aafp.org, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680.

Please include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.

Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the American Academy of Family Physicians permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.



Copyright © 2011 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

Navigate this Article